Skip to main navigation Skip to search Skip to main content

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): A phase I study

  • Suresh Ramalingam
  • , Judy Forster
  • , Cynthia Naret
  • , Terry Evans
  • , Matt Sulecki
  • , Haolan Lu
  • , Paola Teegarden
  • , Martin R. Weber
  • , Chandra Belani

Research output: Contribution to journal › Article › peer-review

52   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): A phase I study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases

Medicine and Dentistry